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Human antimicrobial peptide, 
LL‑37, induces non‑inheritable 
reduced susceptibility 
to vancomycin in Staphylococcus 
aureus
Cathrine Friberg1,3, Jakob Krause Haaber1,4, Martin Vestergaard1, Anaëlle fait1, 
Veronique perrot2, Bruce R. Levin2 & Hanne Ingmer1*
Antimicrobial peptides (AMPs) are central components of the innate immune system providing 
protection against pathogens. Yet, serum and tissue concentrations vary between individuals and 
with disease conditions. We demonstrate that the human AMP LL‑37 lowers the susceptibility to 
vancomycin in the community‑associated methicillin‑resistant S. aureus (CA‑MRSA) strain FPR3757 
(USA300). Vancomycin is used to treat serious MRSA infections, but treatment failures occur despite 
MRSA strains being tested susceptible according to standard susceptibility methods. Exposure to 
physiologically relevant concentrations of LL‑37 increased the minimum inhibitory concentration 
(MIC) of S. aureus towards vancomycin by 75%, and resulted in shortened lag‑phase and increased 
colony formation at sub‑inhibitory concentrations of vancomycin. Computer simulations using a 
mathematical antibiotic treatment model indicated that a small increase in MIC might decrease the 
efficacy of vancomycin in clearing a S. aureus infection. This prediction was supported in a Galleria 
mellonella infection model, where exposure of S. aureus to LL‑37 abolished the antimicrobial effect of 
vancomycin. Thus, physiological relevant concentrations of LL‑37 reduce susceptibility to vancomycin, 
indicating that tissue and host specific variations in LL‑37 concentrations may influence vancomycin 
susceptibility in vivo.
Bacterial resistance to antibiotics is generally associated with genetic changes, such as point mutations in the 
core genome or acquisition of resistance genes present on mobile genetic  elements1, or intrinsic resistance to 
antimicrobials, such as impermeability of the outer membrane of Gram-negative bacteria or the active efflux of 
antimicrobials provided by chromosomally encoded efflux  pumps2. Previously, we showed that exposure to the 
synthetic antimicrobial peptide (AMP) colistin reduces susceptibility to vancomycin in the clinically important, 
methicillin resistant Staphylococcus aureus (MRSA) strain USA300 via induction of the GraRS cell wall  regulon3. 
Staphylococcus aureus is a human pathogen that causes a variety of diseases and particularly the MRSA clones are 
becoming widely distributed both in the hospital environment and in the  community4. MRSA infections are often 
treated with the glycopeptide antibiotic vancomycin. The CLSI susceptibility breakpoint for vancomycin is 2 µg/
ml5. However, in the last decade vancomycin-intermediate S. aureus strains (VISA) have emerged with reduced 
vancomycin susceptibility (MIC = 4–8 μg/ml)6. These strains are characterized by chromosomal mutations that 
reduce negative cell wall  charge7, increase cell wall  thickness8 or reduce Triton-X mediated  autolysis9. Even for 
non-VISA strains vancomycin treatment failures have been linked to strains displaying MIC in the higher end 
of the susceptibility range (≥ 1.5 μg/ml)5,10–13. Our previous work revealed that upon colistin exposure, S. aureus 
cells transiently and reversibly induce cellular changes that result in a phenotypic VISA-like  appearance3. This 
open
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reduced vancomycin susceptibility state will remain undetectable by routine clinical testing and thus the MIC 
of vancomycin upon colistin exposure in vivo may be higher than expected from such testing.
Colistin is a cationic AMP used in treatment of Gram-negative infections, however AMPs are also major com-
ponents of the innate immune system and a critical defence against a large number of  pathogens14. Human AMPs 
are small, often cationic peptides with broad-spectrum antimicrobial activity caused by membrane-damaging 
pore-formation14. An example is the cathelicidin, LL-3715. It is expressed by a variety of immune cells, including 
polymorphonuclear leukocytes (PMN) as well as by epithelial cells and has been identified in saliva, sweat glands, 
and other  tissues16. In keratinocytes, exposure to S. aureus leads to upregulation of LL-37  production17. LL-37 
has broad antimicrobial activity against bacteria, fungi and  viruses16 and in addition is chemotactic for human 
neutrophils, monocytes and T  cells18. Plasma levels of LL-37 in healthy individuals have been measured to be 
approximately 1 µg/ml, but with variations between individuals from 0.5 to 3 µg/ml19. In areas of bacterial infec-
tion the local concentration will reach even higher levels due to de-granulation of PMNs, e.g. in bronchoalveolar 
lavage fluid, where LL-37 concentrations from 5 to 25 µg/ml have been measured in infected  individuals20,21. In 
the present study, we have examined the interplay between LL-37 and vancomycin and we demonstrate that LL-37 
transiently reduces susceptibility to vancomycin. We speculate that natural variation in LL-37 concentrations 
may lead to variation in susceptibility to vancomycin therapy between tissues and individuals.
Materials and methods
Bacterial strains and growth conditions. Staphylococcus aureus USA300  FPR375722 was obtained from 
the American Type Culture Collection (ATCC). Staphylococcus aureus strains were routinely grown in Muel-
ler–Hinton (MH) or cation adjusted MH (MHII) medium (Sigma) at 37 °C in Erlenmeyer flasks with aeration.
Minimum inhibitory concentration. Staphylococcus aureus FPR3757 was diluted to  105 CFU/ml in MH 
or MHII media and incubated for 1 h (200 rpm, 37 °C) with either no, 5, 10 or 20 μg/ml LL-37 (Sigma) followed 
by addition of vancomycin (Sigma). The minimum inhibitory concentration (MIC) was determined in a 96-well 
microtiter plates (200 rpm, 37 °C, 24 h using technical duplicates and biological triplicates) by visual inspection. 
Similar approach was used for determining MIC for LL-37 with increasing LL-37 concentrations and no addi-
tion of vancomycin.
Vancomycin susceptibility testing by plating. Exponential phase S. aureus FPR3757 cultures were 
adjusted to  OD600 = 0.25 in pre-heated MH broth and was then treated with sub-inhibitory concentrations of 
LL-37 (0, 5, 10, 20 and 40 μg/ml) for 1 h. The cultures were adjusted to  OD600 = 0.1 before spotting 10 μl aliquots 
of serial four-fold dilutions on freshly prepared MH agar plates containing increasing concentrations of vanco-
mycin (0, 1, 1.25 and 1.5 μg/ml).
In one experiment, cultures of S. aureus FPR3757 were grown with 10 μg/ml LL-37 for 60 min and LL-37 
was removed from the medium by spinning (5,000 g, 5 min, room temperature) and re-suspended in pre-heated 
MH broth in a subset of the culture, while exposure to LL-37 was maintained in the other subset. After 0, 60 and 
90 min, the cultures where plated on agar plates containing vancomycin (1.5 μg/ml).
The agar plates were inspected for growth following 24 h incubation.
Growth experiments. Overnight cultures were diluted to approx.  105 CFU/ml in fresh MH broth, and 
incubated for 1 h at 37 °C and 200 rpm. The culture was then split in appropriate aliquots and treated with LL-37 
or left untreated for 1 h at 37 °C and 200 rpm. The untreated and pre-treated cultures were then split in appro-
priate aliquots and treated with vancomycin (Sigma) or left untreated. These were then further aliquoted into 
the wells of a 100-well honeycomb plate and incubated in a Bioscreen C Analyzer (Oy Growth Curves Ab Ltd, 
Helsinki, Finland) at 37 °C and medium continuous shaking.
Determination of Triton X‑100 induced autolysis. The setup of the autolysis assay was conducted 
as previously  described3 containing the following changes. Briefly, strains were grown in MH broth at 37 °C, 
180 rpm, to mid-exponential phase. The cultures were diluted to an  OD600 of 0.15 in warm MH, grown to an 
 OD600 of 0.25, and 10 μg/ml LL-37 was added to one subset of cultures while another subset of cultures served 
as the unexposed control. After 1 h, the cultured cells were washed twice in ice-cold sterile distilled water and 
resuspended in the same volume of 0.05 M Tris-HCl (pH 7.2) containing 0.05% Triton X-100. Cells were incu-
bated at 30 °C, and the  OD600 was measured every 30 min. Data are expressed as the percent loss of  OD600 at the 
indicated times compared to findings at time zero. Each data point represents the mean and standard deviation 
from three independent experiments.
A model of antibiotic treatment. To illustrate the relationship between the MIC of vancomycin and the 
course of treatment, we used a simple mathematical model of the population dynamics of antibiotic treatment. 
In this model, we assume Hill function to specify the relationship between the concentration of the antibiotic, A 
(µg/ml), and the rates per cell per hour at which the exposed bacteria grow and/or are  killed23,24.
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The parameter  VMAX > 0 per cell per hour, is the maximum rate of growth of the bacteria in the absence of 
the antibiotic and  VMIN < 0 per cell per hour is the minimum rate of growth of those bacteria in the presence 
of the antibiotic. The parameter κ controls the shape of this function, the greater the value of κ the more acute 
the relationship between the concentration of the antibiotic and the rate of decline in the viable density of the 
 bacteria23. To account for the resource limitation and the fact that as the availability of resources decline the rates 
at which bacteria grow  declines25 we assume a hyperbolic function for the relationship between the resource 
concentration, R (µg/ml), and the rate of growth of the bacteria, R/(R + k), where k, the Monod constant, is 
the concentration of the limiting resource where, in the absence of the antibiotic the rate of the bacteria is half 
its maximum value. Thus, when the concentration of the antibiotic and resource are respectively A and R, the 
growth/death of the bacteria is ψP(A,R) per cell per hour.
We assume the bacteria are maintained in a continuous (chemostat-like) culture of unit volume into which 
the limiting resources, from a reservoir where it is maintained at a concentration C (µg/ml), flow in at a constant 
rate w (ml per hour) with the same rate at which excess resource, bacteria and antibiotics flow  out26. The bacteria 
take up the limiting resource at rates proportional to their maximum growth rates and a conversion efficiency 
parameter, e (µg/cell). With these definitions and assumptions, the rates of change in the density of viable bacte-
ria, P (cells per ml), the limiting resource and antibiotics are expressed as a set of coupled differential equations.
where d is the rate of decay in the concentration of the antibiotic.
To simulate the dynamics of treatment, we solve these equations numerically using Berkeley Madonna. 
Copies of this program are available from blevin@emory.edu. To account for treatment, in these simulations, an 
antibiotic at a concentration of  AMAX (µg/ml) is introduced into the vessel every Dose hours.
Galleria mellonella infection model. Twenty healthy 5th instar larvae each weighing 250  mg were 
injected with 2.5 × 106 CFU of S. aureus FPR3757 followed by 10 µg/ml LL-37 or 0.9% NaCl for controls. One 
hour post infection, the larvae were treated with 15 mg/kg bodyweight of vancomycin, corresponding to a rel-
evant clinical dose. The LL-37 pre-treatment and antimicrobial therapy was repeated every 24 h for a total of 
72 h and survival was monitored. Controls for toxicity of LL-37 combined with the antimicrobials as well as for 
non-treated S. aureus infection were included with all larvae receiving an equal number of injections of either 
active compound or 0.9% NaCl.
Statistics. The data were analyzed in GraphPad Prism 7 (GraphPad Software Inc.) using one-way analysis of 
variance (ANOVA) with a post hoc analysis of Dunnett’s multiple comparison tests, where P < 0.05 (*), P < 0.01 
(**) and P < 0.001 (***). The survival data was analyzed by using the Kaplan–Meier method and statistical differ-
ence determined, using log-rank test.
Results
Pre‑exposure to LL‑37 reduces S. aureus susceptibility to vancomycin. We have previously 
shown that pre-exposure of S. aureus to the antimicrobial peptide, colistin, reduces vancomycin  susceptibility3. 
To address if exposure to the human antimicrobial peptide LL-37 also affects vancomycin susceptibility we 
initially determined the LL-37 MIC of S. aureus FPR3757 to be > 128 μg/ml. As concentrations of LL-37 in the 
range of 0–40 μg/ml are physiologically relevant we pre-treated cells with either 10 or 20 μg/ml LL-37 prior to 
addition of vancomycin. By this approach, we found that in MH the vancomycin MIC increased from 0.8 to 1.2 
and 1.4 μg/ml, respectively, upon exposure to either 10 or 20 μg/ml LL-37. In MHII the increase was from 1.2 
to 1.5 μg/ml following pre-treatment with 20 μg/ml LL-37. We also examined the effect of 5 μg/ml LL-37 and 
found that it did not impact vancomycin susceptibility. To further examine the effect of LL-37 on vancomycin 
susceptibility, we spotted serial dilutions of cultures pre-treated with various sub-inhibitory concentrations of 
LL-37 on agar plates containing increasing concentrations of vancomycin. Cultures exposed to 40 μg/ml LL-37 
were able to form colonies in the presence of 1.5 μg/ml vancomycin in contrast to untreated cells, where no 
growth was observed (Fig. 1).
When observing the growth dynamics of treated and untreated cells in liquid cultures, pre-treatment with 
LL-37 notably reduced the vancomycin induced lag-phase measured as the time from inoculation until density 
reached  OD600 = 0.1 (Fig. 2a,b). In the presence of vancomycin (at 0.75 μg/ml) the lag-phase was 24.5 (± 1.9) h 
for untreated cells, whereas the lag-phase was 8.1 (± 2.5) h following pre-exposure to 20 μg/ml LL-37 (P < 0.001). 
Shortening of the lag phase was proportional to the concentration of LL-37 used for pre-treatment (Fig. 2a,b). In 
the absence of vancomycin, LL-37 treatment did not affect growth kinetics (Fig. 2a). When determining maxi-
mum growth rate, no effect of LL-37 was observed in the vancomycin-treated or control cultures (Figure S1), 
indicating that shortening of lag-phase rather than growth rate is important for the LL-37 induced reduction in 
vancomycin susceptibility.
dR
dt
= w(C − R)− e
R
R + k
VMAXP
dP
dt
= ψP(A,R)P − wP
dA
dt
= −A(w + d)
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LL‑37 induces reversible vancomycin tolerance. To examine if continuous LL-37 exposure is needed 
for the reduced vancomycin susceptibility we monitored the LL-37 exposure time required before being able to 
observe reduced susceptibility to vancomycin and how long the cells retained the reduced susceptibility after 
removal of LL-37. We found that the phenotype was observed already after 10 min of exposure to LL-37 and that 
it lasted approximately 60 min after LL-37 was removed from the growth medium (Fig. 3). These results dem-
onstrate that the reduced vancomycin susceptibility induced by LL-37 exposure is transient and non-inherited.
Effect of LL‑37 on autolysis. Reduced susceptibility to vancomycin in genetically stable VISA strains are 
characterized by an altered cell wall structure that phenotypically can be measured as a decrease in Triton X-100 
induced  autolysis9. We examined the effect of LL-37 exposure (10 µg/ml) on autolysis as described  previously3,7. 
Compared to an un-treated control, the pre-treated culture showed a small but noticeable decrease in Triton 
Figure 1.  LL-37 influences vancomycin susceptibility of S. aureus. Exponential phase S. aureus FPR3757 
cultures were pretreated with 0, 5, 10, 20 and 40 μg/ml LL-37 for 1 h before spotting serial fourfold dilutions on 
MH agar containing increasing concentrations of vancomycin.
Figure 2.  LL-37 influences vancomycin susceptibility of S. aureus in liquid culture. (a) The growth of S. aureus 
FPR3757 with (black lines) or without (grey lines) exposure to 0.75 μg/ml vancomycin after treatment for 
1 h with 0, 5, 10 or 20 μg/ml LL-37. The curves are an average of five replicates. (b) The lag-phase of the same 
cultures depicted in (a) (n = 5). Error bars display 95% confidence intervals. **P < 0.01; *P < 0.05.
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X-100 induced autolysis (Fig. 4) suggesting that LL-37 may impact vancomycin susceptibility via changes in the 
cell wall.
The anticipated relationship between the MIC of vancomycin and the course of treat-
ment. Clinical isolates of vancomycin susceptible MRSA strains with MICs in the higher end of the suscepti-
bility range (≥ 1.5 μg/ml) are linked to vancomycin treatment  failure5. Such treatment failures may be related to 
unidentified host factors, like LL-37, which are causing an increase in S. aureus vancomycin  MIC27. To illustrate 
how, as suggested by clinical  data5, small increases in the MIC of vancomycin may lead to treatment failure, we 
simulated the population dynamics of treatment with the mathematical model described in the “Materials and 
methods” section (Fig. 5). For any given concentration of the antibiotic, the rate at which the bacteria are killed 
declines with the MIC of the antibiotic. While treatment with 2.5 µg/ml will clear the bacteria when the MIC is 
0.8, it will not when the MIC is 1.4, and will only be manifest as a slow decline in the density of the population 
when the MIC is 1.4. To be sure, higher concentrations of the antibiotic will be effective in clearing the infection 
when the MIC is 1.4, but because of toxicity, nephrotoxicity in the case of  vancomycin28, increasing doses of the 
drug is not a clinically amenable solution. Stated in another way, S. aureus exposed to clinically relevant LL-37 
concentrations may have a negative impact on the efficacy of vancomycin for treating infections.
LL‑37 abolishes antimicrobial effect of vancomycin in Galleria mellonella. The observed in vitro 
reduction in vancomycin susceptibility after LL-37 exposure combined with the predictions of treatment fail-
ure associated with modest increments in MIC from our computer model prompted us to test the efficacy of 
vancomycin in treating Galleria mellonella wax moth  larvae29 infected with S. aureus FPR3757 in the pres-
ence or absence of LL-37. In the absence of LL-37, vancomycin reduced the mortality inflicted by the MRSA 
Figure 3.  Transient induction of reduced vancomycin susceptibility by LL-37. (a) Cultures of S. aureus 
FPR3757 were grown without (left) or with (right) 10 μg/ml LL-37 for 10 min and spotted on vancomycin plates 
(1.5 μg/ml). (b) Cultures of S. aureus FPR3757 were grown with 10 μg/ml LL-37 for 60 min and LL-37 was 
removed from the medium in a subset of the culture (left), while exposure to LL-37 was maintained in the other 
subset (right). After 0, 60 and 90 min, the cultures where plated on agar plates containing vancomycin (1.5 μg/
ml).
Figure 4.  LL-37 exposure reduces Triton X-100 mediated autolysis. LL-37 induced autolysis measured as 
reduction of bacterial density over time in a 0.05% Triton X-100 solution containing treated (10 µg/ml LL-37) or 
untreated cultures. Error bars display 95% confidence intervals (n = 3).
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strain. However, in the presence of LL-37, the antimicrobial potential of vancomycin was completely abolished 
(P < 0.001), rendering the larvae as susceptible to S. aureus killing as the non-treated S. aureus infection (Fig. 6).
Discussion
Antimicrobial chemotherapy is currently based on standardized in vitro antimicrobial susceptibility testing, 
however the assay can face limitations in predicting in vivo treatment  efficacy30. The lack of predictive value 
is partly attributed to the fact that the growth media in which the susceptibility tests are conducted, do not 
sufficiently represent the in vivo environment. Several factors, such as nutrient availability, oxygen level, pH 
and presence of innate immune components, have been identified to affect antibiotic susceptibility in both 
Gram-positive and—negative  species31–34. Here we show that the presence of the antimicrobial peptide LL-37 
of the innate immune response antagonizes the activity of vancomycin against S. aureus in vitro. This effect is 
transient and is also evident in the G. mellonella infection model, where the presence of LL-37 with vancomycin 
significantly reduces survival of G. mellonella larvae compared with vancomycin treatment alone. Even though 
only one strain has been investigated and there may be strain to strain variations, our data suggest that the MIC 
values reported from in vitro assays may underestimate the vancomycin MIC in vivo in the presence of LL-37.
Vancomycin is one of the most important antibiotics for treatment of MRSA  infections35. The CLSI suscep-
tibility breakpoint for vancomycin is 2 µg/ml5. Treatment failures reported for infections with MRSA strains 
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Figure 5.  Simulation results of the relationship between the dose of the antibiotic and MIC. Simulations were 
made of treatment every 8 h with a drug (10, 5 and 2.5 µg/ml) of cells with the MIC of 0.8, 1.2 and 1.5 µg/ml of 
the drug and the changes in the viable cell density observed. Hill function parameters  VMAX = 1.0,  VMIN = − 3.0, 
κ = 1.0, continuous culture parameters, k = 1, e = 5 × 10–7, w = 0.5 and C = 1,000 (see the equations in the 
“Materials and methods” section. See supplemental Figure S2 for the pharmacodynamic Hill functions and the 
rates of kill bacteria exposed to antibiotics with these Hill function parameters.
Figure 6.  Influence of LL-37 on vancomycin treatment of S. aureus infecting G. mellonella. Survival of G. 
mellonella wax moth larvae infected with S. aureus FPR3757 and with or without LL-37 (10 µg/ml) exposure 
followed by treatment with vancomycin (15 mg/kg bodyweight). Controls for non-treated S. aureus infection 
and non-infected larvae exposed to combinations of the drugs were included. All larvae received same number 
of injections. n = 20 larvae for each condition.
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being susceptible to vancomycin has led to discussions whether the MIC breakpoint at 2 µg/ml should be further 
 decreased5. A meta-analysis associated high-MIC (≥ 1.5 µg/ml) MRSA isolates with increased risk of mortality 
compared with low-MIC (< 1.5 µg/ml) MRSA  isolates5, thus indicating that even minor increases in vancomycin 
MIC can negatively affect treatment outcome and survival of patients with MRSA infections.
To illustrate how small increases in the MIC of vancomycin can affect treatment outcome due to interaction 
between this drug and LL-37, we used simple mathematical models of the pharmacodynamics of antibiotics 
and bacteria and the course of antibiotic treatment. While the parameter values chosen for this illustration are 
in the range estimated for S. aureus exposed to vancomycin in vitro, these simple simulations certainly do not 
capture the physical, physiologically, and pharmacological heterogeneity of vancomycin treatment of S. aureus 
in an infected host, much less the contribution of the host’s innate and adaptive immune system to the course of 
 treatment36,37. Then again, neither do MICs estimated under in vitro conditions, but in combination they may 
add an additional layer of understanding to the complexity of antimicrobial therapy.
The impact of LL-37 on vancomycin susceptibility under in vivo conditions may vary from person to person. 
As mentioned earlier there is natural variation in the LL-37 levels in healthy individuals that will be increased in 
sites of infection. Furthermore, LL-37 levels are also influenced by disease conditions, where for example psoriasis 
patients have increased LL-37  levels38, while atopic dermatitis patients have reduced  levels39. Thus, there is ample 
evidence for considerable variations in LL-37 levels both from tissue-to-tissue and from person-to-person. Here 
we provide evidence that such variation may influence susceptibility to vancomycin and our results stress the 
need for taking host factors into account when testing susceptibility to antimicrobials.
Collectively, our results indicate that a better understanding of the host’s role in reduced vancomycin suscep-
tibility could be important when designing treatment regimens to improve clinical outcome.
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